Patents Examined by Anoop K. Singh
-
Patent number: 11959091Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.Type: GrantFiled: November 20, 2020Date of Patent: April 16, 2024Assignee: CellectisInventors: Philippe Duchateau, André Choulika, Laurent Poirot
-
Patent number: 11952591Abstract: The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.Type: GrantFiled: March 12, 2020Date of Patent: April 9, 2024Assignee: Janssen Biotech, Inc.Inventors: Sebastian Rieck, Alireza Rezania
-
Patent number: 11946063Abstract: The invention relates to a long DH (LDH) cassette comprising a recombinant DH construct comprising at least two DH gene segments encoding at least 10 amino acids of the HCDR3 amino acid sequence, wherein at least one of the DH gene segments is a heterologous DH gene segment; an immunoglobulin heavy chain locus and a transgenic non-human animal comprising the same; and their use in producing an immunoglobulin library with long HCDR3 regions.Type: GrantFiled: October 19, 2018Date of Patent: April 2, 2024Assignee: TRIANNI, INC.Inventors: Matthias Wabl, Werner Mueller, Peter Burrows, Gloria Esposito, Bao Duong
-
Patent number: 11920160Abstract: Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression.Type: GrantFiled: February 21, 2014Date of Patent: March 5, 2024Assignee: Cedars-Sinai Medical CenterInventors: Dodanim Talavera-Adame, Donald C. Dafoe
-
Patent number: 11920164Abstract: A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.Type: GrantFiled: July 30, 2015Date of Patent: March 5, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Yaqub Hanna, Noa Novershtern, Yoach Rais
-
Patent number: 11913022Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.Type: GrantFiled: January 25, 2018Date of Patent: February 27, 2024Assignee: Cedars-Sinai Medical CenterInventors: Ying Qu, Xiaojiang Cui, Dhruv Sareen, Armando E. Giuliano
-
Patent number: 11910788Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).Type: GrantFiled: January 29, 2021Date of Patent: February 27, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
-
Patent number: 11904001Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.Type: GrantFiled: May 3, 2019Date of Patent: February 20, 2024Assignee: ViaCyte, Inc.Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 11896622Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.Type: GrantFiled: November 8, 2019Date of Patent: February 13, 2024Assignee: ViaCyte, Inc.Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
-
Patent number: 11898163Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.Type: GrantFiled: April 24, 2017Date of Patent: February 13, 2024Assignees: KYOTO UNIVERSITY, SUMITOMO PHARMA CO., LTD.Inventors: Jun Takahashi, Daisuke Doi, Kenji Yoshida, Atsushi Kuwahara, Masayo Takahashi
-
Patent number: 11889821Abstract: The invention provides compositions and methods for enhanced production of immunoglobulin diversity. Specifically, the invention provides compositions and methods for making accessible a B cell receptor repertoire that has not been culled by developmental tolerance mechanisms. The invention also provides transgenic animals, cells, and antibodies resulting from these compositions and methods.Type: GrantFiled: September 23, 2020Date of Patent: February 6, 2024Assignee: TRIANNI, INC.Inventors: Matthias Wabl, Bao Duong, Werner Mueller
-
Patent number: 11890304Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.Type: GrantFiled: September 25, 2019Date of Patent: February 6, 2024Assignee: Janssen Biotech, Inc.Inventor: Jean Xu
-
Patent number: 11885806Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.Type: GrantFiled: June 3, 2022Date of Patent: January 30, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paul Maciocia
-
Patent number: 11885807Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.Type: GrantFiled: June 3, 2022Date of Patent: January 30, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paul Maciocia
-
Patent number: 11884924Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion enzyme editing of nucleic acids in live mammalian cells.Type: GrantFiled: February 14, 2022Date of Patent: January 30, 2024Assignee: Inscripta, Inc.Inventors: Brian Chaikind, Aamir Mir
-
Patent number: 11884935Abstract: The present invention relates to a method for inducing trans-differentiation of cardiomyocytes based on exosome, and more particularly, to a method for inducing trans-differentiation of a fibroblast into a cardiomyocyte, comprising the steps of: isolating exosomes in a culture medium during a process of differentiating a stem cell into the cardiomyocyte; culturing a fibroblast in a cardiomyocyte reprogramming medium containing the isolated exosomes; and culturing the fibroblast cultured in a cardiomyocyte differentiation medium containing the isolated exosomes.Type: GrantFiled: June 28, 2019Date of Patent: January 30, 2024Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Ick Chan Kwon, Sun Hwa Kim, Yoosoo Yang, Hyosuk Kim
-
Patent number: 11872243Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.Type: GrantFiled: January 6, 2020Date of Patent: January 16, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
-
Patent number: 11866767Abstract: Provided herein are methods for simultaneous spatio-temporal measurement of gene expression and cellular activity.Type: GrantFiled: March 7, 2023Date of Patent: January 9, 2024Assignee: 10x Genomics, Inc.Inventors: Cedric Uytingco, Layla Katiraee, Kristen Pham
-
Patent number: 11866733Abstract: Methods are disclosed herein for efficiently generating human induced pluripotent stem cells (iPSC) containing a nucleic acid including a doxycycline promoter operably linked to a nucleic acid encoding Cas9. These methods include transfecting a human somatic cell with a nucleic acid molecule comprising a doxycycline promoter operably linked to a nucleic acid encoding a Cas9, and constitutive promoter operably linked to a tetracycline responsive element and inducing the somatic cell to form an iPSC, thereby producing an iPSC that can undergo CRISPR/Cas9-mediated recombination at a high efficiency. The human iPSC, or a cell differentiated therefrom, is cultured in the presence of doxycycline to induce expression of the Cas9. These cells can then be used to target in any gene of interest by introducing nucleic acids encoding sgRNAs. Induced pluripotent stem cells produced by these methods are also disclosed.Type: GrantFiled: July 31, 2017Date of Patent: January 9, 2024Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alejandro Soto-Gutierrez, Alexandra Sylvie Collin de l'Hortet, Kan Handa, Jorge Guzman Lepe, Yang Wang, Kazuki Takeishi, Ira Jacob Fox
-
Patent number: 11866727Abstract: The present application provides materials and methods for treating a patient with Glycogen Storage Disease type 1a (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.Type: GrantFiled: November 7, 2016Date of Patent: January 9, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Ante Sven Lundberg, Kirsten Leah Beaudry